東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

FindBook

Google Book

Amazon

博客來

MHC Class II Transactivator CIITA as a Potential Therapeutic Target for Amyotrophic Lateral Sclerosis.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	MHC Class II Transactivator CIITA as a Potential Therapeutic Target for Amyotrophic Lateral Sclerosis./
作者:	Leonard, Claudia.
面頁冊數:	1 online resource (68 pages)
附註:	Source: Masters Abstracts International, Volume: 83-12.
Contained By:	Masters Abstracts International83-12.
標題:	Biology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=29168025click for full text (PQDT)
ISBN:	9798438784708

MHC Class II Transactivator CIITA as a Potential Therapeutic Target for Amyotrophic Lateral Sclerosis.
Leonard, Claudia.

MHC Class II Transactivator CIITA as a Potential Therapeutic Target for Amyotrophic Lateral Sclerosis. - 1 online resource (68 pages)

Source: Masters Abstracts International, Volume: 83-12.

Thesis (A.L.M.)--Harvard University, 2022.

Includes bibliographical references

The incidence of ALS is rising, and with onset of the disease usually occurring around 50-60 years of age, an effective treatment is urgent. Many of the proposed ALS pathogenic mechanisms, including neuroinflammation and oxidative stress, are currently being investigated. However, the effect of antigen presentation on ALS disease progression is unknown. Therefore, my goal for this project is to uncover therapeutic targets for ALS centered on: 1) the expression of MHC class II genes, encoded by the two proteins of the HLA-DR heterodimeric complex in humans and 2) regulation of the cytoskeleton, through genes such as MYBPC2 and RAB4B. The transactivator CIITA regulates the transcription of these MHC class II proteins; a process that contributes greatly to immunocompetence. Based on our recent unpublished findings about the downregulation of the HLA-DR genes in cell lines with ALS-causative mutations, we hypothesize that loss of their master regulator CIITA plays a role in ALS. Since microglia are the immune cells of the central nervous system, we will examine CIITA, HLA-DR, CD74, MYBPC2 and RAB4B expression in the microglial cell line HMC3, as well as in HeLa cells to study the basic science of these ALS-causative proteins. This study, if successful, could lay the groundwork for small molecule drug screening for CIITA agonists as a new strategy for discovering treatments for ALS.

Electronic reproduction.
Ann Arbor, Mich. :
ProQuest,
2023

Mode of access: World Wide Web

ISBN: 9798438784708Subjects--Topical Terms:

522710
Biology.
Subjects--Index Terms:

ALS pathogenic mechanismsIndex Terms--Genre/Form:

542853
Electronic books.

MHC Class II Transactivator CIITA as a Potential Therapeutic Target for Amyotrophic Lateral Sclerosis.
LDR:02722nmm a2200361K 4500 001 2359755
005 20230917195237.5
006 m o d
007 cr mn ---uuuuu
008 241011s2022 xx obm 000 0 eng d
020 $a 9798438784708
035 $a (MiAaPQ)AAI29168025
035 $a AAI29168025
040 $a MiAaPQ $b eng $c MiAaPQ $d NTU
100 1 $a Leonard, Claudia. $3 3700374
245 1 0 $a MHC Class II Transactivator CIITA as a Potential Therapeutic Target for Amyotrophic Lateral Sclerosis.
264 0 $c 2022
300 $a 1 online resource (68 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Masters Abstracts International, Volume: 83-12.
500 $a Advisor: Morris, James; Reed, Robin.
502 $a Thesis (A.L.M.)--Harvard University, 2022.
504 $a Includes bibliographical references
520 $a The incidence of ALS is rising, and with onset of the disease usually occurring around 50-60 years of age, an effective treatment is urgent. Many of the proposed ALS pathogenic mechanisms, including neuroinflammation and oxidative stress, are currently being investigated. However, the effect of antigen presentation on ALS disease progression is unknown. Therefore, my goal for this project is to uncover therapeutic targets for ALS centered on: 1) the expression of MHC class II genes, encoded by the two proteins of the HLA-DR heterodimeric complex in humans and 2) regulation of the cytoskeleton, through genes such as MYBPC2 and RAB4B. The transactivator CIITA regulates the transcription of these MHC class II proteins; a process that contributes greatly to immunocompetence. Based on our recent unpublished findings about the downregulation of the HLA-DR genes in cell lines with ALS-causative mutations, we hypothesize that loss of their master regulator CIITA plays a role in ALS. Since microglia are the immune cells of the central nervous system, we will examine CIITA, HLA-DR, CD74, MYBPC2 and RAB4B expression in the microglial cell line HMC3, as well as in HeLa cells to study the basic science of these ALS-causative proteins. This study, if successful, could lay the groundwork for small molecule drug screening for CIITA agonists as a new strategy for discovering treatments for ALS.
533 $a Electronic reproduction. $b Ann Arbor, Mich. : $c ProQuest, $d 2023
538 $a Mode of access: World Wide Web
650 4 $a Biology. $3 522710
650 4 $a Epidemiology. $3 568544
653 $a ALS pathogenic mechanisms
653 $a Amyotrophic Lateral Sclerosis
653 $a Lou Gehrig's disease
655 7 $a Electronic books. $2 lcsh $3 542853
690 $a 0306
690 $a 0766
710 2 $a ProQuest Information and Learning Co. $3 783688
710 2 $a Harvard University. $b Extension Studies. $3 3560717
773 0 $t Masters Abstracts International $g 83-12.
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=29168025 $z click for full text (PQDT)